April 4 (Reuters) - ANI Pharmaceuticals Inc - Deal For $2.6 Mln And A Limited Single ::ANI ACQUIRES 23 ANDAS FROM IDT AUSTRALIA, LTD..DIGIT ROYALTY FOR ONE PRODUCT.
Full Article
Feb 27 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR RESULTS, REPORTS FOURTH QUARTER 2017 RESULTS, AND PROVIDES 2018 GUIDANCE.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.08.Q4 REVENUE ROSE 24 PERCENT TO $47.3 MILLION.QTRLY GAAP NET LOSS INCLUDES IMPACT OF $13.4 MILLION CHARGE DUE TO TAX CUTS AND JOBS ACT.QTRLY DILUTED GAAP LOSS PER SHARE OF $0.83.SEES 2018 NET REVENUES OF $212 MILLION TO $228 MILLION.SEES 2018 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.43 TO $6.08.PLANS TO INVEST APPROXIMATELY $7 MILLION IN CAPITAL PROJECTS DURING 2018.
Full Article
Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.
Full Article
Nov 2 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance.Q3 adjusted Non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $0.40.Q3 revenue $48.2 million versus I/B/E/S view $48.1 million.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc sees for full year 2017 net revenues $181 million to $183 million.ANI Pharmaceuticals Inc sees for full year 2017 adjusted Non-GAAP diluted earnings per share $3.83 to $4.00.Q3 earnings per share view $0.99, revenue view $48.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.84, revenue view $182.1 million -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc - ANI intends to request a meeting with fda in Q4 of 2017 to present its regulatory filing plan.
Full Article
Sept 1 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals Inc announces approval and launch of Oxycodone Hydrochloride oral solution, 100 mg/5ml.ANI Pharmaceuticals Inc - ANI expects to begin shipping oxycodone hydrochloride oral solution, 100 mg/5ml to its customers immediately.ANI Pharmaceuticals Inc - received approval from U.S. FDA of its ANDA for Oxycodone Hydrochloride oral solution USP, 100 mg/5 ml.
Full Article
Aug 3 (Reuters) - Ani Pharmaceuticals Inc :Ani Pharmaceuticals reports record second quarter and year-to-date 2017 results and reaffirms guidance.Q2 adjusted non-GAAP earnings per share $0.98.Q2 GAAP earnings per share $0.23.Q2 revenue $44.8 million versus I/B/E/S view $43.2 million.Q2 earnings per share view $0.86 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $181 million to $190 million.Ani Pharmaceuticals Inc says reaffirms guidance for full year 2017.FY 2017 revenue view $182.6 million -- Thomson Reuters I/B/E/S.
Full Article
June 20 (Reuters) - Ani Pharmaceuticals Inc :Ani Pharmaceuticals Inc - announced launch of diphenoxylate hcl and atropine sulfate tablets, 2.5mg/0.025mg.
Full Article
June 12 (Reuters) - ANI Pharmaceuticals Inc :Files for mixed shelf of up to $350.0 million .
Full Article
May 8 (Reuters) - Ani Pharmaceuticals Inc :Ani pharmaceuticals announces launch of pindolol tablets.Ani pharmaceuticals inc - launch of pindolol tablets, 5mg and 10mg, which is used in treatment of hypertension.
Full Article
May 4 (Reuters) - Ani Pharmaceuticals Inc ::Ani Pharmaceuticals reports first quarter results and year-to-date 2017 highlights and reaffirms guidance.Q1 adjusted non-gaap earnings per share $0.74.Q1 GAAP earnings per share $0.10.Q1 revenue rose 78 percent to $36.6 million.Sees FY 2017 revenue $181 million to $190 million.Ani Pharmaceuticals Inc - reaffirms guidance.Ani Pharmaceuticals Inc - ANI reaffirms guidance for full year 2017.FY2017 earnings per share view $3.87, revenue view $186.9 million -- Thomson Reuters I/B/E/S.
Full Article
Earnings vs. 
Estimates